Puma Biotechnology (PBYI) Q1 2025 earnings summary

Executive summary

• Q1 2025 net income was $3.0 million ($0.06/share), reversing a net loss of $4.8 million in Q1 2024, with total revenue at $46.0 million, primarily from NERLYNX sales.

• Net product revenue from NERLYNX was $43.1 million, up 7% year-over-year but down 21% sequentially, with 2,338 bottles sold and 72% of new patients starting at reduced doses.

• Ongoing clinical trials include phase one and two studies for new indications and combinations, with interim data for alisertib expected in H2 2025.

• NERLYNX commercialization continues in the US and over 50 countries, with new launches and distribution agreements in regions including Libya, Eastern Europe, Central Asia, and other global markets.

• Operating costs and expenses declined year-over-year, and new patient education resources and revised sales aids were launched to improve persistence and compliance.

Financial highlights

• Net product revenue for NERLYNX was $43.1 million, up from $40.3 million year-over-year, while royalty revenue was $2.9 million, down from $3.5 million.

• Cost of sales for Q1 2025 was $10.6 million, including $2.4 million in amortization of intangible assets.

• SG&A expenses were $17.6 million (down 19% year-over-year), and R&D expenses were $13.8–$13.9 million (up 2%).

• Cash, cash equivalents, and marketable securities totaled $93.2 million as of March 31, 2025, with operating cash flow of $3.6 million.

• Gross-to-net adjustment in Q1 2025 was 20.8%, up from 18.2% in Q4 2024.

Outlook and guidance

• FY 2025 net NERLYNX product revenue is expected to be $192–$198 million, with royalty revenue projected at $20–$24 million.

• FY 2025 net income guidance is $23–$28 million; Q2 2025 net product revenue expected at $48–$50 million.

• SG&A expenses anticipated to decrease 5–10% and R&D expenses to increase 10–15% year-over-year.

• Management expects current cash and equivalents to fund operations for at least one year.

• Key clinical milestones for alisertib trials anticipated in H2 2025.